Related references
Note: Only part of the references are listed.Effect of IBD medications on COVID-19 outcomes: results from an international registry
Ryan C. Ungaro et al.
GUT (2021)
From intravenous to subcutaneous infliximab in patients with inflammatory bowel disease: a pandemic-driven initiative
Ajay M Verma et al.
Lancet Gastroenterology & Hepatology (2021)
Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis
William J. Sandborn et al.
GASTROENTEROLOGY (2020)
OP23 Efficacy and safety of vedolizumab SC in patients with moderately to severely active Crohn’s disease: Results of the VISIBLE 2 study
S Vermeire et al.
Journal of Crohns & Colitis (2020)
British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic
Nicholas A. Kennedy et al.
GUT (2020)
Understanding and Minimising Injection-Site Pain Following Subcutaneous Administration of Biologics: A Narrative Review
Anja St Clair-Jones et al.
RHEUMATOLOGY AND THERAPY (2020)
A vedolizumab population pharmacokinetic model including intravenous and subcutaneous formulations for patients with ulcerative colitis
M. Rosario et al.
JOURNAL OF CROHNS & COLITIS (2019)
Vedolizumab exposure levels and clinical outcomes in ulcerative colitis: determining the potential for dose optimisation
Mark T. Osterman et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2019)
Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease
Sebastian Zeissig et al.
GUT (2019)
Are abatacept and tocilizumab intravenous users willing to switch for the subcutaneous route of administration? A questionnaire-based study
Marie Desplats et al.
CLINICAL RHEUMATOLOGY (2017)
Low Fecal Calprotectin Correlates with Histological Remission and Mucosal Healing in Ulcerative Colitis and Colonic Crohn's Disease
Eran Zittan et al.
INFLAMMATORY BOWEL DISEASES (2016)
Randomized Crossover Comparison of Injection Site Pain with 40 mg/0.4 or 0.8mL Formulations of Adalimumab in Patients with Rheumatoid Arthritis
Peter Nash et al.
RHEUMATOLOGY AND THERAPY (2016)
Implications of subcutaneous or intravenous delivery of trastuzumab; further insight from patient interviews in the PrefHer study
L. Fallowfield et al.
BREAST (2015)
Intravenous versus Subcutaneous Drug Administration. Which Do Patients Prefer? A Systematic Review
Kelly L. Stoner et al.
PATIENT-PATIENT CENTERED OUTCOMES RESEARCH (2015)
Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNF alpha therapy: results from the COIN study
Mirthe Emilie van der Valk et al.
GUT (2014)
Development and validation of a rapid, generic measure of disease control from the patient's perspective: the IBD-Control questionnaire
Keith Bodger et al.
GUT (2014)
Mucosal Healing in Inflammatory Bowel Disease
Mark T. Osterman
JOURNAL OF CLINICAL GASTROENTEROLOGY (2013)
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
Brian G. Feagan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
A systematic review of evidence on the links between patient experience and clinical safety and effectiveness
Cathal Doyle et al.
BMJ OPEN (2013)
Systematic assessment of factors influencing preferences of crohn's disease patients in selecting an anti-tumor necrosis factor agent (CHOOSE TNF TRIAL)
Stephan R. Vavricka et al.
INFLAMMATORY BOWEL DISEASES (2012)
How do patients with inflammatory bowel disease want their biological therapy administered?
Patrick B. Allen et al.
BMC GASTROENTEROLOGY (2010)
Share Paper
